ANIXA BIOSCIENCES, INC. Available-for-sale Securities, Amortized Cost Basis
ANIXA BIOSCIENCES, INC. (ANIX) had Available-for-sale Securities, Amortized Cost Basis of $16.20 million as of 2012-10-31, per its 10-Q/A filed 2013-03-25.
Discontinued › Notes › Investments
us-gaap:AvailableForSaleSecuritiesAmortizedCost · last filed 2013-03-25
- 2012-10-31: Available-for-sale Securities, Amortized Cost Basis $16.20M.
- 2012-07-31: Available-for-sale Securities, Amortized Cost Basis $16.20M.
| Period end | Available-for-sale Securities, Amortized Cost Basis |
|---|---|
| 2012-10-31 | $16.20M 10-Q/A · filed 2013-03-25 |
| 2012-07-31 | $16.20M 10-Q · filed 2012-09-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CITIUS ONCOLOGY, INC. (CTOR) | United States | $0.097B | -1.49 |
| Milestone Pharmaceuticals Inc. (MIST) | $0.098B | -2.00 | |
| Acrivon Therapeutics, Inc. (ACRV) | United States | $0.091B | -1.03 |
| ProMIS Neurosciences Inc. (PMN) | $0.102B | ||
| Rallybio Corp (RLYB) | United States | $0.089B | |
| Polaryx Therapeutics, Inc. (PLYX) | United States | $0.106B | |
| ONCOLYTICS BIOTECH INC (ONCY) | $0.086B | ||
| NEONC TECHNOLOGIES HOLDINGS, INC. (NTHI) | United States | $0.086B | |
| Biomea Fusion, Inc. (BMEA) | United States | $0.107B | -3.30 |
| Lexaria Bioscience Corp. (LEXX) | $0.084B | -1.92 |